Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging

08/18/2021 | 07:24pm EDT

Hexima Limited announced that it has filed a design patent covering important consumer oriented designs of the proposed commercial packaging for pezadeftide, its proprietary product in development to treat onychomycosis. Hexima will hold an investor webinar on 2 September 2021 (AEST) to discuss the importance of the design covered in the patent. The commercial package is intended to enhance the experience of patients using pezadeftide to treat their onychomycosis. In the webinar, the company will also introduce the design of a mobile application Hexima intends to implement as a companion application to facilitate patients connecting with their doctor, monitoring treatment progress, up-loading photographs, and refilling prescriptions. Two aspects of consumer attractiveness are built in with company product. First, pezadeftide appears to work very rapidly delivering a patient-friendly and convenient short course of therapy. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA).1 Onychomycosis is an infectious disease and is difficult to treat with significant healthcare burden. It causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.2 Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations.2 The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.

© S&P Capital IQ 2021
All news about HEXIMA LIMITED
10/05Hexima Limited Announces Company Secretary Change
09/253,559,437 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
08/31Jake Nunn Joins Board of Hexima Limited as Non-Executive Director, effective 1 Septembe..
08/27HEXIMA : 2021 Annual Financial Report
08/27Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2021
08/27Hexima Limited Auditor Raises 'Going Concern' Doubt
08/24HEXIMA : Secures Chinese Patent for Fungal Nail Infection Treatment; Shares Surge 12%
08/18Hexima Limited Announces Design Patent for Pezadeftide Commercial Packaging
07/25Hexima Limited Announces Completion of Enrolment in Phase IIb Clinical Trial
07/13HEXIMA : Expects to Secure European Patent for Nail Fungal Infection Treatment
More news
Sales 2021 4,08 M 3,04 M 3,04 M
Net income 2021 -6,87 M -5,12 M -5,12 M
Net cash 2021 3,39 M 2,52 M 2,52 M
P/E ratio 2021 -2,77x
Yield 2021 -
Capitalization 47,8 M 35,4 M 35,6 M
EV / Sales 2020 -
EV / Sales 2021 4,62x
Nbr of Employees -
Free-Float 38,3%
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Executive Director & Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.220.51%130 866
LONZA GROUP AG26.90%58 060
SEAGEN INC.-1.81%31 426
CELLTRION, INC.-39.69%25 414